| + 5% improvement in LV-EF | + 10% improvement in LV-EF | ||||
---|---|---|---|---|---|---|
Adjusted OR | 95% CI | p-value | Adjusted OR | 95% CI | p-value | |
Age (per +1 year) | 0.965 | 0.937–0.993 | 0.015 | 0.975 | 0.949–1.002 | 0.070 |
Male sex | – | – | – | 0.271 | 0.125–0.584 | 0.001 |
Hypertension | 0.521 | 0.278–0.975 | 0.042 | – | – | – |
SGLT2i | 2.384 | 1.266–4.488 | 0.007 | 2.236 | 1.106–4.521 | 0.025 |
Standard dose of beta-blockers for HFa | – | – | – | 2.849 | 1.126–7.205 | 0.027 |
LV-EDV (per +1 mL) | 0.987 | 0.977–0.996 | 0.007 | – | – | – |
LV-EF (per +1%) | 0.919 | 0.891–0.948 | < 0.001 | 0.928 | 0.906–0.950 | < 0.001 |
PASP (per +1 mmHg) | 1.025 | 1.000–1.051 | 0.049 | – | – | – |